Indivior seeks injunction to block Dr. Reddy’s generic launch in US

By Flora Southey contact

- Last updated on GMT

(Image: Getty/bandit2523)
(Image: Getty/bandit2523)
Indivior has requested a temporary restraining order against Dr. Reddy’s Laboratories to prevent further sales of its generic buprenorphine and naloxone sublingual film product in the US.

Indivior has sought an injunction against Dr. Reddy’s after the Indian drugmaker – in collaboration with Mylan – received US Food and Drug Administration (FDA) approval for a generic alternative to Indivior’s Suboxone sublingual film.

The June 14 approval​ marked the first entry of a generic Suboxone product to enter the US market. The film is comprised of buprenorphine to help supress opioid withdrawal symptoms, and naloxone, which reverses and blocks narcotic effects.

But on June 15, Indivior expressed concerns that ongoing patent litigation between the parties – regarding US Patent No. 8,603,514​ – had not been resolved before launch.

“We are surprised by Dr. Reddy’s decision to launch ‘at risk’ given the ongoing litigation and associated significant risk to them of substantial economic damages if, as we believe, we eventually prevail in protecting the Suboxone Film patent estate,” ​said Indivior’s CEO Shaun Thaxter in a statement​.

According to Indivior, a generic version of Suboxone Film in the US could result in a “rapid and material loss of market share”​ within months of launching a generic film alternative.

“In the meantime, we will continue to pursue all legal avenues, including an immediate injunction until the legal status of our intellectual property is confirmed by the Courts,” ​said Thaxter

Dr. Reddy’s responds

On June 16​, Dr. Reddy’s defended its right to launch the sublingual product in the US.

The Indian drugmaker clarified the proceeding relates to US Patent No. 9,931,305​ only, and does not prohibit commercial manufacturing of the product, adding, “the plaintiffs will be required to post a bond or other security totalling $18m [€15.5m] to satisfy any losses or damages incurred by Dr. Reddy’s during the period of the temporary restraining order.

“The court has scheduled an expedited hearing of the preliminary injunction for Thursday, June 28, and a ruling is expected soon thereafter.”

Related topics: Markets & Regulations, Regulations

Related news

Show more

Related products

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us


View more